Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of General Internal Medicine, Department of Medicine, University Health Network and Sinai Health, University of Toronto, Toronto, Ontario, Canada.
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Can J Diabetes. 2024 Oct;48(7):462-470.e3. doi: 10.1016/j.jcjd.2024.07.002. Epub 2024 Jul 26.
Diabetic ketoacidosis (DKA) occurring after diabetes diagnosis is often associated with risk factors for other diabetes-related complications. In this study, we aimed to determine the prognostic implications of DKA on all-cause mortality and complications in type 1 diabetes (T1D).
Previously collected data from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study were obtained through the the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository. Using Cox proportional hazards models with time-dependent covariates, we examined age- and sex-adjusted, glycated hemoglobin-adjusted, and fully adjusted associations of DKA with all-cause mortality, cardiovascular disease, microvascular complications, and acute complications over 34 years.
Of the 1,441 study participants, 297 had 488 DKA events. Prior DKA was associated with a higher risk of age- and sex-adjusted all-cause mortality (hazard ratio [HR] 8.28, 95% confidence interval [CI] 3.74 to 18.32, p<0.001), major adverse cardiovascular events (MACEs) (HR 2.05, 95% CI 1.34 to 3.13, p<0.001), and all advanced microvascular and acute complications compared with no prior DKA. Most associations except retinopathy were significant even after adjustment for covariates. In our fully adjusted analysis, prior DKA was associated with a significantly higher risk of subsequent all-cause mortality (HR 9.13, 95% CI 3.87 to 21.50, p<0.001), MACEs (HR 1.66, 95% CI 1.07 to 2.59, p=0.03), advanced kidney disease (HR 2.10, 95% CI 1.00 to 4.22, p=0.049), advanced neuropathy (HR 1.49, 95% CI 1.05 to 2.13, p=0.03), severe hypoglycemia (HR 1.53, 95% CI 1.28 to 1.81, p<0.001), and recurrent DKA (HR 3.24, 95% CI 2.41 to 4.36, p<0.001) compared with person-time without DKA.
DKA is a prognostic marker for diabetes complications, including excess all-cause mortality. Intensified clinical interventions, such as cardiovascular prevention strategies, may be warranted after diagnosis of DKA.
糖尿病酮症酸中毒(DKA)在诊断糖尿病后发生,常与其他糖尿病相关并发症的危险因素相关。本研究旨在确定 DKA 对 1 型糖尿病(T1D)全因死亡率和并发症的预后意义。
通过国家糖尿病、消化和肾脏疾病研究所中央存储库,获取糖尿病控制和并发症试验/糖尿病干预和并发症的流行病学(DCCT/EDIC)研究中先前收集的数据。使用具有时间依赖性协变量的 Cox 比例风险模型,我们检查了 DKA 与全因死亡率、心血管疾病、微血管并发症和 34 年内急性并发症的年龄和性别调整、糖化血红蛋白调整和完全调整的关联。
在 1441 名研究参与者中,297 人发生了 488 次 DKA 事件。既往 DKA 与年龄和性别调整的全因死亡率(风险比 [HR] 8.28,95%置信区间 [CI] 3.74 至 18.32,p<0.001)、主要不良心血管事件(MACEs)(HR 2.05,95%CI 1.34 至 3.13,p<0.001)和所有高级微血管和急性并发症的风险增加相关,与既往无 DKA 相比。除视网膜病变外,大多数关联在调整协变量后仍然显著。在我们的完全调整分析中,既往 DKA 与随后全因死亡率(HR 9.13,95%CI 3.87 至 21.50,p<0.001)、MACEs(HR 1.66,95%CI 1.07 至 2.59,p=0.03)、晚期肾脏疾病(HR 2.10,95%CI 1.00 至 4.22,p=0.049)、晚期神经病变(HR 1.49,95%CI 1.05 至 2.13,p=0.03)、严重低血糖(HR 1.53,95%CI 1.28 至 1.81,p<0.001)和复发性 DKA(HR 3.24,95%CI 2.41 至 4.36,p<0.001)的风险显著增加,与无 DKA 时的人时相比。
DKA 是糖尿病并发症的预后标志物,包括全因死亡率增加。在诊断 DKA 后,可能需要强化临床干预,如心血管预防策略。